Clinical

A phase 3 trial in symptomatic and anemic patients with myelofibrosis (MF) met its primary end point, seeing a significant symptom reduction at 24 weeks with momelotinib vs danazol.

The reported neurofilament light elevation preceding confirmed disability worsening events highlighted the value of NfL as an early biomarker of disability worsening and points to the existence of different windows of dynamic central nervous system pathology.

The tool assesses the risk of heart attack, stroke, and, for the first time, heart failure, offering a more comprehensive perspective on cardiovascular health.

Repotrectinib achieved a high objective response rate and durable response in the pivotal TRIDENT-1 trial.

The CDC has published updated recommendations for the postexposure prevention and treatment of Bacillus anthracis (anthrax) infection; the FDA has granted marketing approval to an at-home chlamydia and gonorrhea test; lawmakers and Veterans Affairs officials acknowledge the potential for psychedelic drugs to treat veterans’ mental health conditions and prevent suicide.

According to researchers, the most prevalent risk factors in children with type 1 spinal muscular atrophy (SMA) are hypercalciuria and elevated urine specific gravity.

With improved survival becoming more common among individuals who have Duchenne muscular dystrophy (DMD), cardiomyopathy is also increasing in prevalence among this population.

Remibrutinib, an investigational, highly selective Bruton tyrosine kinase inhibitor, showed favorable results in the treatment of chronic spontaneous urticaria (CSU) in as early as 2 weeks in the phase 3 REMIX-1 and REMIX-2 studies.

Heart failure treatment strategies are emphasized based off recent clinical trial data.

Utilization of the four pillars in heart failure therapy are highlighted as aggressive first-line treatment strategies.

Male adolescent and young adult patients were found to have an increased risk of keratoconus if they had attention-deficit/hyperactivity disorder (ADHD), regardless of confounders.

Patients with chronic obstructive pulmonary disease (COPD) who were from minority ethnic backgrounds were found to have lower adherence to treatment interventions compared with the general population.

Michael Fang, PhD, researcher and assistant professor in the division of Cardiovascular and Clinical Epidemiology at Johns Hopkins University, discussed recent findings in the type 1 diabetes (T1D) space that may alter the way providers address diabetes diagnoses.

New research highlighted how aspirin is unnecessary in antithrombotic regimens for patients with advanced heart failure and fully magnetically levitated left ventricular assist devices (LVADs).

Patients who have HIV and are using antiretroviral therapy (ART) did not have adverse outcomes when using nivolumab for cancer treatment.

To combat C difficile, Christian John Lillis, cofounder and executive director of the Peggy Lillis Foundation for C. Diff Education & Advocacy, noted that awareness and innovation must continue to increase.

This new study sought to solidify a relationship between certain microbes in intestinal flora and the risk of developing myasthenia gravis, specifically those potentially reducing that risk.

A retrospective analysis of data from the US National Inpatient Sample revealed the prevalence of fibromyalgia and chronic fatigue syndrome was significantly increased in patients with IBS compared with those without IBS.

With the recent development of various new treatments, April Armstrong, MD, MPH, discusses the new standards she and other dermatologists hope to set for treating patients with atopic dermatitis (AD).

Patients with sickle cell disease (SCD) who wore an Apple Watch and reported daily pain scores could have their pain scores accurately predicted during hospital admission for vaso-occlusive crises and after discharge.

Insight surrounding the switch from reference drugs to biosimilars is provided by Bincy Abraham, MD, MS.

Vibeke Strand, MD, evaluates implementation of biosimilars in patients with no history of reference biologic use.

Compared with those without chronic obstructive pulmonary disease (COPD), patients with both sepsis and COPD had higher intensive care unit (ICU) mortality rates, longer ICU stays, and higher in-hospital mortality rates.

Up to 30 million individuals could lose Medicaid coverage; a new initiative demands increased focus on women's health issues; survey reports increased 5-year lung cancer survival rates from 2015 to 2019.

Posters presented at ACAAI 2023 Annual Scientific Congress assessed digital health tools to improve asthma self-management.

The strongest associations between diabetes and colorectal cancer risk were observed in participants with a recent diabetes diagnosis and those who had not undergone recent colonoscopy, underscoring the significance of cancer screening.

Cost-effectiveness considerations are highlighted by Dr Abou-Alfa.

Treatment continuity and adherence in HCC can be encouraged through patient education and engagement.

Two posters presented at the 2023 Fall Clinical Dermatology Conference assessed phase 4 study findings on tildrakizumab in patients with moderate to severe plaque psoriasis.

This new research sheds light on the importance of follow-up meetings for young patients discharged from emergency departments (EDs).